Data for Patient-derived procoagulant breast fibroblasts

We hypothesised that this procoagulant phenotype correlates with a CAF-like phenotype and that fibroblasts distant from the immediate TME are less procoagulant.

We also proposed that the procoagulant phenotype contributes functionally to breast cancer progression.</p><p dir="ltr">File contains the data for the Figures in the Ogunlayi et al. paper (2025) written on this topic.</p><p dir="ltr">Acronyms/Abbreviations: <b>CM</b>: Conditioned Media, <b>Fib</b>: Fibroblasts <b>IBC</b>: Invasive Breast Cancer, <b>Rep</b>: Replicate <b>SN</b>: Same breast Normal (Same breast as IBC), <b>TF</b>: Tissue Factor, <b>TFi</b>: Tissue Factor inhibition<b> </b>(monoclonal anti-TF antibody 10H10) <b>TF-OE</b>: Tissue Factor-Over Expressing, <b>TGFBRi</b>: TGFBR inhibitor (SB-431542).</p><p dir="ltr"><br></p><p>Techniques Used:</p><p dir="ltr">Figure 1- Immunocytochemistry (H-Score), Procoagulant activity assay (Clotting times), TF activity assay (TF concentration, pM).</p><p dir="ltr">Figure 2- Western Blotting (expression normalised), ELISA (TGF beta 1 concentration), Procoagulant activity assay (Clotting times).</p><p dir="ltr">Figure 3- Immunocytochemistry (H-Score), ELISA (TGF beta 1 concentration), Procoagulant activity assay (Clotting times), TF activity assay (TF concentration, pM).</p><p dir="ltr">Figure 4- TF activity assay (TF concentration, pM), Scratch wound migration assay (rate).</p><p dir="ltr">Supplementary Data- Immunocytochemistry (H-Score).</p><p dir="ltr"><br></p>